Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Earnings

Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update

By The Northwire Desk — AI Analysis Nov 26, 2025 · 07:36 SHRX · 3.95 Sharp Therapeutics Corp.
SHRX · Price

Executive Summary

  • Sharp Therapeutics released its condensed interim consolidated financial statements for the three‑month and nine‑month periods ended September 30, 2025.
  • Management highlighted a 34% increase in R&D spending versus the comparable quarter in 2024, underscoring progress toward Phase I clinical trials slated for 2026.
  • No specific revenue or profit figures were disclosed; the release is primarily an informational filing of interim financials and MD&A.

Key Details

  • Condensed interim consolidated financial statements cover the three‑month (Q3) and nine‑month periods ended September 30, 2025.
  • All dollar amounts are presented in United States dollars unless otherwise noted.
  • CEO/CSO Scott Sneddon stated that Q3 results reflect continued investment in R&D programs for Gaucher disease, Niemann‑Pick C, and Progranulin targets.
  • R&D expenditures increased by 34% compared with the same quarter in 2024, supporting advancement toward Phase I clinical trials anticipated in 2026.
  • The release includes a Management Discussion & Analysis (MD&A) accompanying the financial statements.

Notable Quotes

“Our Q3 financial results show our continued investment in research and development programs… We spent 34% more than the comparable quarter in 2024 which continues to move the Company towards Phase I clinical trials.” – Scott Sneddon, CEO/CSO

Read the original news release →

More from Sharp Therapeutics Corp.

May 28, 2026 · 16:00

Sharp Therapeutics Expands NPC Pipeline with Preclinical Data Amidst Ongoing Capital Raise

Other Apr 17, 2026 · 18:14

Sharp Therapeutics Secures Tranche Financing Amidst Pipeline Pivot and Contingent Equity Hurdles

Earnings Apr 10, 2026 · 17:05

Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

Production / Operations Apr 10, 2026 · 17:00

Sharp Therapeutics Advances Clinical Pipeline Amidst Capital Raise and Lead Compound Optimization

Financings Apr 02, 2026 · 17:43

Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

Financings Mar 13, 2026 · 17:06

Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

Financings